It is too early to know whether the prompt response to the virus is enough to turn the tide
Also in this newsletter: How greener corporate car fleets could boost competitiveness and the climate goals
Swiss pharma group is a high spender on R&D but has had misses in Alzheimer’s and cancer
Emmanuel Hanon criticises former company’s drug after he raises $100mn for rival product
More aggressive actions and better co-ordinated responses needed to contain viruses, say public health experts
Issue hampers effort to exploit mRNA technology’s promise in tackling deadly viral outbreaks
Wealthy world must help Africa prevent a potential regional health catastrophe
Jab makers fall behind Moderna in post-pandemic market with disappointing results
EU court rules that European Commission unlawfully withheld information about procurement
New agreement hands UK drugmaker control of developing jabs and provides cash injection for German group
Pfizer and BioNTech infringed pharmaceutical group’s mRNA patent, High Court in London rules
Pharma group dealt another blow following decision by British to award vaccine contract to rival Pfizer
Vaccine maker to seek approval for jab as it tries to diversify product pipeline
As Covid revenues slump, technology developed to fight the pandemic is having some success combating this disease
So-called FLiRT strains set to test effectiveness of vaccines against latest mutations
Decision is a boon for the mRNA-vaccine maker in its legal fight to recoup pandemic profits from rivals
Drugmaker follows Eli Lilly in cutting out middlemen and selling directly to patients
Agreement worth up to $1.2bn includes plan for combined flu and Covid shots
Saving humanity’s a costly business
Anglo-Swedish drugmaker says availability of newer vaccines hit demand for jab
Xi Jinping hopes manufacturing can offset the property slump
Moderna alleges Pfizer and BioNTech infringed its patents in use of mRNA platform
Shah Capital wants change in US biotech’s strategy as its shares have tumbled since their pandemic peak
Pledges to invest in pandemic preparedness with facility in Kenya fall short as sales of Covid jabs decline
Not only is the cost-benefit ratio unbeatable, but not to undertake this spending is to court disaster
